iRhythm Technologies (IRTC) to Release Quarterly Earnings on Thursday

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) is projected to announce its Q2 2025 earnings results after the market closes on Thursday, July 31st. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $173.94 million for the quarter. iRhythm Technologies has set its FY 2025 guidance at EPS.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.06). iRhythm Technologies had a negative net margin of 15.90% and a negative return on equity of 101.04%. The business had revenue of $158.68 million during the quarter, compared to analyst estimates of $153.39 million. During the same period last year, the business earned ($1.23) EPS. The business's quarterly revenue was up 20.3% compared to the same quarter last year. On average, analysts expect iRhythm Technologies to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

iRhythm Technologies Stock Performance

Shares of NASDAQ:IRTC traded up $1.89 during trading on Friday, hitting $134.18. 184,629 shares of the stock were exchanged, compared to its average volume of 414,071. iRhythm Technologies has a 1-year low of $55.92 and a 1-year high of $157.13. The company has a market capitalization of $4.28 billion, a price-to-earnings ratio of -42.73 and a beta of 1.41. The company's fifty day simple moving average is $142.46 and its 200-day simple moving average is $120.95. The company has a debt-to-equity ratio of 7.47, a quick ratio of 5.58 and a current ratio of 5.71.

Analyst Upgrades and Downgrades

IRTC has been the topic of several recent research reports. Morgan Stanley decreased their price objective on iRhythm Technologies from $160.00 to $147.00 and set an "overweight" rating on the stock in a report on Tuesday, July 15th. Canaccord Genuity Group decreased their price objective on iRhythm Technologies from $152.00 to $139.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Citigroup upped their price target on iRhythm Technologies from $130.00 to $167.00 and gave the company a "buy" rating in a research report on Thursday, May 22nd. Wall Street Zen cut shares of iRhythm Technologies from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. Finally, Robert W. Baird lifted their price target on shares of iRhythm Technologies from $133.00 to $150.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $137.30.

Insider Activity at iRhythm Technologies

In other iRhythm Technologies news, insider Chad Patterson sold 936 shares of the business's stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $150.00, for a total value of $140,400.00. Following the completion of the transaction, the insider directly owned 48,929 shares of the company's stock, valued at approximately $7,339,350. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Daniel G. Wilson sold 3,000 shares of the business's stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $150.00, for a total value of $450,000.00. Following the completion of the transaction, the chief financial officer directly owned 40,307 shares of the company's stock, valued at approximately $6,046,050. The trade was a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,356 shares of company stock worth $796,882. 1.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its stake in iRhythm Technologies by 33.5% in the first quarter. Goldman Sachs Group Inc. now owns 433,780 shares of the company's stock valued at $45,408,000 after acquiring an additional 108,941 shares during the period. Royal Bank of Canada boosted its position in shares of iRhythm Technologies by 423.0% during the first quarter. Royal Bank of Canada now owns 7,573 shares of the company's stock worth $793,000 after buying an additional 6,125 shares during the period. Finally, Strs Ohio acquired a new position in shares of iRhythm Technologies during the first quarter worth about $147,000.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.